{"denomUnitsSelected":"Participants","description":"Categorical data analysis and logistic regression will be used to evaluate the associations between PD-L1 expression (by IHC) and clinical outcome (e.g., response, clinical benefit, progression-free survival, and survival). Kaplan-Meier methodology and Cox proportional hazards models will be used to evaluate time to event endpoints.","reportingStatus":"NOT_POSTED","timeFrame":"Up to 3 years","title":"PD-L1 Expression Assessed Using Immunohistochemistry (IHC)","type":"OTHER_PRE_SPECIFIED"}